The Impact of Perimenopause on Endometriosis

Endometriosis, a chronic gynaecological condition characterised by the presence of endometrial-like tissue outside the uterus, affects approximately 10% of reproductive-aged individuals assigned female at birth. This tissue responds to hormonal fluctuations, leading to inflammation, pain, and infertility. The transition to menopause, known as perimenopause, is marked by significant hormonal changes that can influence the course of endometriosis. This blog explains why endometriosis can get worse during perimenopause. It looks at the changes in hormones, the body's physical changes, and what this means for medical treatment.

Hormonal Dynamics of Perimenopause

Perimenopause is a transitional phase that typically begins in the 40s, lasting several years until the onset of menopause, defined as 12 consecutive months without menstruation. During this period, ovarian function declines, leading to erratic and often elevated levels of estrogen and a gradual decrease in progesterone.

1. Estrogen Fluctuations:

Estrogen is an important hormone that affects endometriosis, a condition where tissue similar to the lining of the uterus grows outside it. This tissue reacts strongly to estrogen, which makes it grow and spread. During perimenopause, which is the transition period before menopause, estrogen levels can go up and down unpredictably. These sudden increases in estrogen can make endometriosis symptoms worse because they cause the endometrial-like tissue to grow and become more inflamed. When estrogen levels are high, it creates a situation where endometriosis can continue to exist and even get worse.

2. Progesterone Deficiency:

Progesterone is another important hormone that helps balance the effects of estrogen. It works by slowing down the growth of endometrial tissue and reducing inflammation through its impact on the immune system. During perimenopause, progesterone levels start to drop, weakening its balancing effect on estrogen. Without enough progesterone, estrogen's effects are not kept in check, which can lead to more growth of the endometrial-like tissue. This imbalance, with less progesterone and more unchecked estrogen, can make endometriosis worse, causing more symptoms and discomfort.

Physiological and Immunological Changes

In addition to hormone changes, several body and immune system changes during perimenopause can affect endometriosis.

1. Altered Immune Response:

Endometriosis involves a disrupted immune system. Normally, the immune system helps remove endometrial-like cells that grow outside the uterus. However, in endometriosis, this process doesn't work well. During perimenopause, the immune system changes further, including a drop in the activity of natural killer cells, which are part of the body's defence system, and changes in the levels of cytokines, which are signalling proteins in the immune system. These changes can make the immune system less effective at clearing out endometrial-like cells. As a result, the endometriosis tissue can persist and even worsen because the body's natural defence is weaker.

2. Inflammatory Environment:

Endometriosis is known for causing chronic inflammation, which means ongoing irritation and swelling in the tissues. Perimenopause can increase overall inflammation in the body due to factors like changes in how fat is distributed and how it functions. This increased inflammation can make endometriosis symptoms worse by causing more inflammatory responses in the endometrial-like tissue. This leads to more pain and discomfort, as the already inflamed tissue becomes even more irritated during perimenopause.

Clinical Implications

Understanding these changes is important for managing endometriosis during perimenopause. As hormone levels fluctuate and the immune system changes, women with endometriosis may experience more severe symptoms. Treatments may need to be adjusted to address both the hormonal and immune system changes, providing better relief and improving quality of life.

Clinical Implications and Management Strategies

The potential worsening of endometriosis during perimenopause presents significant clinical challenges. Effective management requires a nuanced understanding of the hormonal and physiological changes occurring during this transition.

Perimenopause can make endometriosis worse, creating challenges for doctors. To manage it well, they need to understand the complex changes in hormones and the body that happen during this time.

Hormonal Therapies:

To manage endometriosis during perimenopause, doctors often use hormonal therapies to balance estrogen levels and address low progesterone. Here’s a closer look at these treatments and how they work:

1. Combined Oral Contraceptives:

   • What They Are: These are birth control pills that contain both estrogen and progestin (a synthetic form of progesterone).

   • How They Work: They help regulate the menstrual cycle and keep hormone levels steady. By providing consistent levels of estrogen and progestin, they can reduce the growth of endometrial-like tissue and decrease pain and other symptoms of endometriosis.

2. Progestins:

   • What They Are: Progestins are synthetic versions of progesterone, available in various forms such as pills, injections, or intrauterine devices (IUDs).

   • How They Work: They work by counteracting the effects of estrogen on the endometrial-like tissue. Progestins help shrink the tissue and reduce inflammation, which can alleviate pain and other symptoms. They also prevent the lining of the uterus from thickening, which can help control abnormal bleeding.

3. Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists:

   • What They Are: These are medications that affect the release of hormones from the brain that control the reproductive system. GnRH agonists initially increase and then significantly decrease the production of estrogen, while GnRH antagonists lower estrogen levels directly.

   • How They Work: By lowering estrogen levels, these medications reduce the stimulation of endometrial-like tissue. This helps decrease the size and activity of endometriosis lesions, leading to reduced pain and other symptoms. GnRH agonists and antagonists can create a temporary menopause-like state, providing relief from endometriosis symptoms.

These hormonal therapies aim to stabilise hormone levels, reduce the growth of endometrial-like tissue, and alleviate symptoms associated with endometriosis. By understanding and effectively using these treatments, doctors can help manage the condition during the challenging perimenopausal period.

Surgical Options:

When medical treatments are not enough to manage endometriosis, surgery might be needed. Here’s a detailed look at the surgical options and considerations:

Laparoscopic Excision of Endometriotic Lesions:

• What It Is: Laparoscopic surgery is a minimally invasive procedure where small incisions are made, and a camera (laparoscope) is used to guide the surgical instruments. Surgeons can see and remove endometriotic lesions through these small cuts.

• How It Works: The surgeon locates and excises (cuts out) the endometrial-like tissue growing outside the uterus. This removal can reduce pain and other symptoms by eliminating the source of inflammation and abnormal tissue growth.

Benefits of Surgery:

• Symptom Relief: By removing the lesions, many patients experience significant relief from pain and other symptoms related to endometriosis.

• Improved Quality of Life: Reducing or eliminating symptoms can greatly improve daily functioning and overall quality of life for those affected by severe endometriosis.

Risks and Considerations:

• Surgical Risks: As with any surgery, there are risks such as infection, bleeding, and complications from anaesthesia. Laparoscopic surgery, being minimally invasive, generally has a lower risk profile compared to open surgery, but risks still exist.

• Perimenopausal Considerations: During perimenopause, individuals might have other health issues, such as cardiovascular problems, diabetes, or obesity, which can increase the risk of surgical complications. The decision to undergo surgery should take these comorbidities into account.

• Potential for Recurrence: While surgery can provide relief, there is a possibility that endometriosis can recur, especially if the hormonal environment remains conducive to the growth of endometrial-like tissue.

Decision-Making Process:

• Thorough Evaluation: A detailed assessment by a healthcare provider is crucial to determine if surgery is the best option. This includes evaluating the severity of symptoms, the extent of the disease, and the overall health of the patient.

• Balancing Risks and Benefits: The potential benefits of surgery, such as symptom relief and improved quality of life, need to be weighed against the risks, especially for those with additional health concerns. A comprehensive discussion between the patient and their healthcare team is essential to make an informed decision.

In summary, while laparoscopic excision of endometriotic lesions can be an effective option for those not responding to medical management, it requires careful consideration of the individual’s overall health and specific circumstances during perimenopause.

Conclusion

Endometriosis during perimenopause is influenced by complex hormonal dynamics, physiological changes, and altered immune responses. The unpredictable fluctuations in estrogen levels and the decline in progesterone create a hormonal environment that can make things worse. Additionally, systemic inflammatory changes and impaired immune function during perimenopause contribute to the persistence and potential worsening of the condition. Understanding these mechanisms is crucial for developing effective management strategies to improve the quality of life for individuals undergoing this transition. Further research is needed to explore the long-term impact of perimenopause on endometriosis and to optimise therapeutic approaches.

References

• Agarwal N, Subramanian A. Endometriosis - morphology, clinical presentations and molecular pathology. J Lab Physicians. 2010 Jan;2(1):1-9. doi: 10.4103/0974-2727.66699. PMID: 21814398; PMCID: PMC3147077.

• Mowers EL, Lim CS, Skinner B, Mahnert N, Kamdar N, Morgan DM, As-Sanie S. Prevalence of Endometriosis During Abdominal or Laparoscopic Hysterectomy for Chronic Pelvic Pain. Obstet Gynecol. 2016 Jun;127(6):1045-1053. doi: 10.1097/AOG.0000000000001422. PMID: 27159755.

• Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Curr Obstet Gynecol Rep. 2017 Mar;6(1):34-41. doi: 10.1007/s13669-017-0187-1. Epub 2017 Jan 27. PMID: 29276652; PMCID: PMC5737931.

• Zondervan, K. T., Becker, C. M., Missmer, S. A. (2020). Endometriosis. The New England Journal of Medicine, 382(13), 1244-1256. doi:10.1056/NEJMra1810764

• Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019 Nov;15(11):666-682. doi: 10.1038/s41574-019-0245-z. Epub 2019 Sep 5. PMID: 31488888.

• Andres, M. P., Borrelli, G. M., Ribeiro, J., Baracat, E. C., Abrão, M. S., & Kho, R. M. (2020). Transvaginal ultrasound for diagnosis of deep endometriosis: A systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 301(6), 1441-1452. doi:10.1007/s00404-020-05516-4

• Vannuccini, S., Tosti, C., Carmona, F., Huang, S. J., Chapron, C., Guo, S. W., & Petraglia, F. (2017). Pathogenesis of adenomyosis: an update on molecular mechanisms. Reproductive Biomedicine Online, 35(5), 592-601. doi:10.1016/j.rbmo.2017.06.016

• Brichant, G., & Donnez, J. (2017). Laparoscopic management of endometriosis. Current Opinion in Obstetrics and Gynecology, 29(4), 243-248. doi:10.1097/GCO.0000000000000373

• Becker, C. M., Gattrell, W. T., Harris, T., & Fraser, I. S. (2017). Targeting angiogenesis to treat endometriosis. Expert Opinion on Therapeutic Targets, 21(7), 675-686. doi:10.1080/14728222.2017.1340837